Karyopharm Therapeutics Inc. has announced its preliminary unaudited financial outlook for 2025, projecting total revenue of approximately $145 million and U.S. XPOVIO® (selinexor) net product revenue of about $115 million for the full year. The company aims to maintain its commercial presence in the increasingly competitive multiple myeloma market and drive further growth in XPOVIO revenues. Karyopharm also continues to support global launches of selinexor in ex-U.S. territories and is preparing for upcoming potential regulatory filings and commercialization efforts, particularly with anticipated transformative clinical trial data expected in 2026. No significant variations in business performance for the disclosed period were highlighted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE60458) on January 12, 2026, and is solely responsible for the information contained therein.